VC Playbook

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.

Strategic partnerships and disciplined spending are emerging as key survival tools in challenging funding environment.

For biotech CEOs navigating today’s capital crunch, understanding what sophisticated investors actually look for can mean the difference between a successful raise and months of rejected pitches.

Investors and healthcare philanthropists have launched a new women’s health fund – aiming to be the largest of its kind – with an ambitious goal to not just finance innovation, but to build a sustainable market around it.

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

In Vivo looks at the top partnerships and investments in AI-driven companies in 2024. Collaborations and investments spanned multiple therapeutic areas, with a particular focus on small molecule discovery, protein degradation and neurological diseases.

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.  

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

VC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.  

VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”  

Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.